Amphion Innovations PLC Director/PDMR Shareholding (3471E)

TIDMAMP

RNS Number : 3471E

Amphion Innovations PLC

09 February 2015

Amphion Innovations plc

("Amphion" or "the Company")

(LSE: AMP)

Directors' Dealings

Directors Receive Shares in Lieu of Fees

Amphion Innovations, a developer of medical, life science, and technology businesses, announces that the Company has today issued 344,471 ordinary shares, representing 0.23% of the enlarged issued share capital, to certain of its Board members as their directors' fees for the first quarter of 2015, priced at 3.250 pence, being the average of the closing mid-market price for the five days leading up to the market close on 5 February 2015. Following this issue, the directors' shareholdings in the Company are as follows:

 
Director             Number of New Shares  Total Shareholding  Percentage of voting rights 
Miroslaw Izienicki   81,250                    183,333          0.123% 
R. James Macaleer    216,346               25,811,881          17.367% 
Gerard Moufflet      46,875                 1,086,458           0.731% 
 

Admission of the 344,471 new ordinary shares, ranking pari passu with the existing ordinary shares, is expected on 16 February 2015. Following this allotment the total issued share capital of the Company will increase to 148,622,977 ordinary shares with each share holding one voting right.

For further information please contact:

Amphion Innovations plc

Charlie Morgan

[phone]

Yellow Jersey PR

Dominic Barretto / Fiona Walker

[phone]

Plumtree Capital Limited (Financial Advisor)

Stephen Austin

London: [phone]

New York: [phone]

Panmure Gordon Limited (Nominated Advisor and Broker)

Freddy Crossley / Fred Walsh / Duncan Monteith (Corporate Finance)

Charlie Leigh-Pemberton (Corporate Broking)

[phone]

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: www.amphionplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSVQLFBELFXBBL